- Conditions
- Parkinson's Disease
- Interventions
- LY3962681, Placebo (aCSF)
- Drug · Other
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Englewood, Colorado • New Haven, Connecticut • Naples, Florida + 4 more
Parkinson's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Parkinson's Disease. Browse Parkinson's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Parkinson's Disease studies are organized in the registry
Records generally use the registry spelling “Parkinson disease.” The portfolio mixes drug studies with a high share of device, exercise, and rehabilitation research, so the study-type filter is unusually useful here. Disease-stage language (“early,” “advanced,” “levodopa-treated”) commonly appears in titles.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Parkinson Disease
- Interventions
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Biological
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Naples, Florida
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
- Interventions
- 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease
- Interventions
- 150% of their routine home dopaminergic medications dose right in the clinic, Evaluation of mathematical models
- Drug · Device
- Lead sponsor
- Stardots AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Manchester, New Hampshire
- Conditions
- Parkinson Disease
- Interventions
- CREXONT ER
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Parkinson Disease
- Interventions
- Summit RC+S
- Device
- Lead sponsor
- Doris Wang, MD, PhD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Parkinson Disease
- Interventions
- Movement task
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders, Genetic Predisposition
- Interventions
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Behavioral
- Lead sponsor
- Radboud University Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
- Interventions
- DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
- Radiation · Genetic · Procedure + 1 more
- Lead sponsor
- Douglas Scharre
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Parkinson Disease, Mild Cognitive Impairment
- Interventions
- Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Parkinson Disease
- Interventions
- LY4006896, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Los Alamitos, California • Maitland, Florida • Naples, Florida + 7 more
- Conditions
- Parkinson Disease, Parkinson Disease Dementia, Lewy Body Parkinson Disease, Lewy Body Dementia With Behavioral Disturbance
- Interventions
- neuropsychiatric and cognitive testing questionnaires
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
About this Parkinson's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Parkinson's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Parkinson's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Parkinson's Disease.